meetings

ISPE 2013 Mid-Year Symposium Agenda

April 12, 2013
Hilton Munich City, Munich, Germany

Planning Committee:

Co-chairs: Joerg Hasford, University of Munich; Frank Andersohn, Charite University Medicine Berlin

Members: Dorothee Bartels, Boehringer Ingelheim; Stella Blackburn, FISPE, European Medicines Agency; Edeltraut Garbe, University of Bremen; Tobias Gerhard, FISPE, Rutgers University; Michael Lewis, FISPE, EPES Epidemiology; Marie Lindquist, Uppsala Monitoring Centre; Yola Moride, FISPE, Universite de Montréal; June Raine, MHRA; Nancy Santanello, FISPE, Merck Research Laboratories; Raymond Schlinger, Novartis; Sebastian Schneeweiss, FISPE, Harvard Medical School; John Seeger, Brigham & Women’s Hospital; Miriam Sturkenboom, FISPE, University Medical Center; Petra Thürman Helios-Kliniken; Olaf Klungel, Utrecht University; Corinne de Vries, FISPE, European Medicines Agency; Mark Epstein, ISPE; Andrew Jerdonek, ISPE

Thursday, April 11: Pre-Symposium Courses/Scientific Program Committee (no exhibits)
-Additional registration required *

  • 8:30am-12:30pm Introduction to Pharmacoepidemiology *
     
  • 8:30am-12:30pm 2013 ICPE Scientific Program Committee
     
  • 1:30pm-5:30pm Advanced Topics in Pharmacoepidemiology *

Friday, April 12: ISPE Mid-Year Symposium
Table-top exhibits open 8:00am-4:00pm

  • 8:00am-4:00pm Registration
     
  • 8:30-8:45am Welcome from the Program Chairs and ISPE President
    —Joreg Hasford, Co-Chair, Planning Committee
    —Frank Andersohn, Co-Chair, Planning Committee
    —Stella Blackburn, FISPE, President
     
  • Drug Risk Assessment in Older Adults, Held Jointly with Clinical Division of IUPHAR.
    This session will feature four 25-minute presentations with time for questions.

    Chair:
    —Petra Thürmann, Helios-Kliniken

    Presentations:
    • Age and Co-morbidity of Patients in Clinical Trials vs. “Real Patients”
      —Darrell Abernethy, US Food & Drug Administration, USA
       
    • Understanding Interactions Between Medicines and Geriatric Syndromes: The Role of Pharmacoepidemiology
      —Sarah Hilmer, Royal North Shore Hospital, Australia
       
    • Sedative Drug Load in the Elderly and Adverse Outcomes
      —Sirpa Hartikainen, University of Eastern Finland, Finland
       
    • o Prescribing Potentially Inappropriate Medication: A Quality Indicator for Drug Prescription?
      —Petra Thürmann, Helios-Kliniken, Germany
       
  • 10:25-10:50am Break with Exhibitors
     
  • 10:55am-12:35pm The Pharmacoepidemiology of New Antithrombotics
    This session will feature four 25-minute presentations with time for questions.

    Chair:
    —Edeltraudt Garbe, University of Bremen

    Presentations:
    • Clinical Pharmacolgy of Novel Antithrombotic Drugs
      —Reinhold Kreutz, Institut Fuer Klinische Pharmakologie, Germany
    • Challenges of Registries and Observational Studies of New Oral Anticoagulants.
      —Dorothee Bartels, Boehringer Ingelheim, Germany
    • Rivaroxaban or Standard of Care for Thromboprophylaxis After Major Orthopaedic Surgery
      —Lorenzo Mantovani, University of Naples, Italy
    • Prospective Safety Monitoring of Prasugrel vs.Clopidogrel Using Claims Databases
      —Joshua Gagne, Brigham and Women's Hospital, USA
  • 12:35-1:30pm Networking Lunch
    Included in registration fee
     
  • 1:35- 3:25pm: First Results from PROTECT
    This session will feature five presentations with time for questions.

    Chairs: Olaf Klungel, Utrecht University and Robert Reynolds, FISPE, Pfizer

    Speakers:
    • Why is PROTECT So Important for the EMA and Drug Safety in Europe?
      —Stella Blackburn, FISPE, European Medicines Agency, United Kingdom
    • Comparative analyses of Drug-Adverse Event Associations in Various European Databases
      —Raymond Schlienger, Novartis Pharma, Switzerland
      —Mark de Groot, Utrect, Utrecht University The Netherlands
    • Propensity Scores and Instrumental Variables to Control for Confounding
      —Rolf Groenwold, Utrecht University, The Netherlands
    • Access to Reliable Drug Utilization Data in Europe
      —Luisa Ibanez, Fundacio Institut Catala Farmacologia, Spain
    • Future Directions of Benefit-Risk Assessment in Europe
      —Deborah Ashby, Imperial College London, United Kingdom
  • 3:25-3:50pm Break with Exhibitors
     
  • 3:55- 5:35pm: Comparative Effectiveness Research
    This session will feature four 25-minute presentations with time for questions.

    Chair: Sebastian Schneeweiss, FISPE, Harvard Medical School, USA

    Presentations:
    • Comparative Effectiveness Research in Coverage Decision Making
      —Jürgen Windeler, Institute for Quality and Efficiency in Health Care, Germany
    • Pharmacoepidemiology in Pharmaceutical Gain/Risk-Sharing Programs: How Well Does CER do?
      —Adrian Towse, Office of Health Economics, United Kingdom
    • Adaptive Licensing and Implications for Comparative Effectiveness Research
      —Hans-Georg Eichler, European Medicines Agency, United Kingdom
    • Large Simple Trials in Comparative Effectiveness Research
      —Tom MacDonald, FISPE, University of Dundee, United Kingdom
  • 5:35-5:50pm Final Comments; ICPE 2013
    —Joreg Hasford, Co-Chair, Planning Committee
    —Frank Andersohn, Co-Chair, Planning Committee
    —Yola Moride, FISPE, Chair, 2013 ICPE Scientific Program Committee
     
  • 5:50pm
    Adjournment